Form 8-K · Current Report · Filed 2026-05-19
Amgen Announces Retirement of CFO Peter Griffith and Appointment of Thomas Dittrich
On May 19, 2026, Amgen Inc. announced the retirement of Peter H. Griffith, its Executive Vice President and Chief Financial Officer, effective August 31, 2026. Griffith will remain with the company until January 2027 in a non-executive role to ensure a smooth transition. Thomas Dittrich has been appointed as Griffith's successor, effective September 1, 2026. Dittrich, who previously held senior finance roles at Amgen, brings over 30 years of international leadership experience. His compensation package includes an annual base salary, equity awards, and relocation benefits.
- Filer
- Amgen Inc. AMGN · NASDAQ
- Filed
- Accession
- 0000318154-26-000097
- CIK
- 0000318154
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$324.39
Next session
+2.2%
Since filing
+18.7%
Latest close
$385.16
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from AMGN reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, AMGN insiders reported 59 Form 4 transactions — net buying of $67.9M.
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Never miss another AMGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.